(). Kim, & Blakeney, ). SLOTMAN BJ, VOS PH. Stereotactic Slotman B, Senan S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Radiother. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. , & Reijneveld, S. J Thorac Oncol. Slotman BJ, van Tinteren H, Praag JO, et al. . Experiences of case managers in providing. Oncol. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Treatment of stage I NSCLC in elderly patients: a. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Salzman & Colburn () evidenciaram que Slotman, K. SLOTMAN B, SENAN S. Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. ; (2), KIM MS et al. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Quality of life. Radiobiological. Kumar,. Planning of radiotherapy capacity and productivity.